S. Weiss

发表

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

R. Recker, J. Rodriguez-Portales, J. Dequeker, 1996 .

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.

Meehyung Cho, Claude Gagné, B. Gumbiner, 2002, The American journal of cardiology.

Significant Differential Effects of Alendronate, Estrogen, or Combination Therapy on the Rate of Bone Loss after Discontinuation of Treatment of Postmenopausal Osteoporosis

S. Greenspan, A. Mulloy, S. Weiss, 2002, Annals of Internal Medicine.

Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial.

I. Kourides, S. Weiss, W. Landschulz, 2003, Archives of internal medicine.

Biological Variability of Serum and Urinary N‐Telopeptides of Type I Collagen in Postmenopausal Women

R. Eastell, M. Pettinger, M. Ettinger, 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.

R. Recker, S. Greenspan, A. Mulloy, 2000, The Journal of clinical endocrinology and metabolism.

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.

P. Sambrook, J. Rodriguez-Portales, G. Fuleihan, 2000, The Journal of clinical endocrinology and metabolism.

Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.

M. Mercuri, J. Kastelein, D. Hunninghake, 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Low-Dose Esterified Estrogen Therapy: Effects on Bone, Plasma Estradiol Concentrations, Endometrium, and Lipid Levels

H. Genant, N. Watts, J. Lucas, 1997 .

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

J Dequeker, R. Recker, J. Rodriguez-Portales, 1995, The New England journal of medicine.

Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group.

H. Genant, N. Watts, J. Lucas, 1997, Archives of internal medicine.

Nutrition and Type-1 Diabetes Mellitus

S. Weiss, 2006 .

A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group.

S. Weiss, M. Dolker, H. Ellman, 1999, Obstetrics and gynecology.

Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals.

S. Schwartz, H. Haber, S. Weiss, 1997, The American journal of cardiology.

Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study

Roy A Kaplan, J. McGill, I. Hirsch, 1998, Diabetes Care.

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

T. Schnitzer, D. Krupa, K. Cerchio, 2001, The Journal of clinical endocrinology and metabolism.

LOW-DOSE ESTERIFIED ESTROGEN THERAPY : EFFECTS ON BONE, PLASMA ESTRADIOL CONCENTRATIONS, ENDOMETRIUM, AND LIPID LEVELS

H. Genant, N. Watts, J. Lucas, 1998 .

Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients

A. Dobs, E. Stein, H. Bays, 1998 .

Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia

J. Mckenney, D. Hunninghake, J. Isaacsohn, 2001, Clinical cardiology.

Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study.

Stanley Heshka, Steven B Heymsfield, G. Bray, 2003, JAMA.

Efficacy and Safety of Acarbose in Insulin-Treated Patients With Type 2 Diabetes

D. Schimel, D. Kelley, Z. Freedman, 1998, Diabetes Care.

A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss

S. Weiss, M. Dolker, H. Ellman, 1999 .

A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.

J. Mckenney, L. McCormick, S. Weiss, 1998, The American journal of medicine.

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

J. Isaacsohn, R. Goldstein, V. Miller, 1996, JAMA.

The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic Patients

J. Mckenney, D. Hunninghake, S. Weiss, 1998, PharmacoEconomics.

The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study.

J. Mckenney, E. Stein, L. Shurzinske, 1996, Clinical therapeutics.

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.

J. Isaacsohn, B. Gordon, S. Weiss, 1999, Archives of internal medicine.

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.

D. Sprecher, S. Schwartz, H. Haber, 1995, Arteriosclerosis, thrombosis, and vascular biology.

A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatin

D. Hunninghake, M. McGovern, R. Brazg, 2003, Clinical cardiology.

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.

D R Illingworth, D. Hunninghake, D. Illingworth, 1997, The American journal of cardiology.

Effects of simvastatin, an HMG‐CoA reductase inhibitor, in patients with hypertriglyceridemia

J. Mckenney, R. Krauss, A. Dobs, 2003, Clinical cardiology.

Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.

A. Dobs, E. Stein, H. Bays, 1998, The American journal of cardiology.

Reduction of LDL-C by more than 60% with the HMG-CoA reductase inhibitor atorvastatin

D. Sprecher, S. Schwartz, H. Haber, 1994 .

Differential Effects of Alendronate and Estrogen on the Rate of Bone Loss After Discontinuation of Treatment: P-80.

S. Greenspan, A. Mulloy, S. Weiss, 1999 .

Time- and dose-dependent effects of corticotropin releasing factor on cerebral glucose metabolism in rats

U. Freo, S. Weiss, C. Ori, 2005, Journal of Neural Transmission.